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Abstract
The maintenance of mitochondrial DNA (mtDNA) relies on proteins encoded
by nuclear genes. Mutations in their coding sequences result in heterogenous
clinical presentations featuring mtDNA instability in affected tissues. DNA2 is a
multi-catalytic protein involved in the removal of single strand DNA during
mtDNA replication or Long Patch Base Excision Repair pathway. We have pre-
viously described DNA2 mutations in adult patients affected with familial and
sporadic forms of mitochondrial myopathy. Here we describe four novel pro-
bands presenting with limb weakness associated with novel DNA2 molecular
defects. Biochemical assays were established to investigate the functional effects
of these variants.
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Introduction
Several mechanisms occur in the nuclear and mitochon-
drial (mtDNA) genome to preserve DNA integrity. Muta-
tions in nuclear genes encoding enzymes devoted to
mtDNA homeostasis result in heterogenous clinical pre-
sentations collectively termed “mtDNA maintenance dis-
orders”.1 These enzymes often feature multiple catalytic
activities engaged during mtDNA repair, replication or
transcription.2
An example is DNA2, a multi-catalytical (helicase/nu-
clease) protein found in mammalian mitochondria, where
it participates in the removal of damaged bases in the
Base Excision Repair (BER) pathway and the removal of
RNA primers during mtDNA replication.3 We have previ-
ously identified DNA2 missense mutations in adult
patients presenting with progressive myopathy and muscle
mtDNA deletions (MIM 615156).4 Since then, DNA2
mutations have been detected in Seckel syndrome (MIM
615807)5 and congenital myopathy.6,7
Here we further expand the number of cases harboring
DNA2 defects.
Subjects and Methods
Subjects
The study was approved by the local ethics committees and
was performed in accordance with the Declaration of Hel-
sinki. Informed consent was obtained from all participants.
Clinical, instrumental and molecular findings are summa-
rized in Table 1. Family pedigrees are shown in Figure S1.
Patient 1 came to our attention at 76 years of age. She
displayed bilateral ptosis since the age of 34. At 54 years
she complained of back pain, muscle cramps and walking
difficulties. She underwent surgery for endometrial cancer.
Additional symptoms included arterial hypertension,
essential tremor, cataract and diabetes. Her mother was
asymptomatic. Her father also had bilateral ptosis and
tremor. She died from lung cancer at 83 years of age.
Family history of paternal lineage was positive for lung
and gastrointestinal neoplasia. The proband’s younger sis-
ter (now 68 years old) also complains of back pain and
walking difficulties. The proband’s daughter is asymp-
tomatic while her son suffers of back pain. Muscle biopsy
(biceps), performed at 70 years of age, showed the pres-
ence of scattered (0.17%) COX-negative/SDH-positive
fibers and a single Ragged Red fiber (0.03%).
Patient 2 is a 56-year-old man with a 6-year history of
progressive limb-girdle muscle weakness, lower limb
hypotonia and exercise intolerance. He walks with a
walker. Additional symptoms include peripheral neuropa-
thy and cataract. His family history is unremarkable for
neuromuscular disorders. His neurological conditions
remained relatively stable in the last 10 years.
His mother died at the age of 52 year from liver can-
cer. COX-negative (2.3%) and Ragged Red fibers (2.9%)
were detected at muscle biopsy (quadriceps), performed
at the age of 56 years.
Patient 3 is a 70-year-old woman with a 5-year history
of mild bilateral ptosis, without ophthalmoplegia, revealed
by ophthalmological examination and probably present
since a few years before. Her family history was negative
for ptosis. She underwent electrophysiological and
Table 1. Clinical, instrumental and molecular findings of the patients described in the study.
Patient Gender
Age
(years)
Age at
Onset
(years) Clinical Features EMG Muscle Biopsy
DNA2
mutation mtDNA
P1 F 76 34 Ptosis, myalgia, diabetes, cataract N COX- (0.17%)
RRF (0.03%)
c.1919C > T,
p.Ser640Leu
mtDNA dels (SB,
long range PCR)
P2 M 56 30 Limb-girdle weakness, hypotonia,
peripheral neuropathy, cataract.
M COX- (2.3%)
RRF (2.9%)
c.2867G > A,
p.Arg956His
mtDNA dels (SB,
long range PCR)
P3 F 70 65 Ptosis N COX- (0.2%) c.1655C > T,
p.Ser552Leu
mtDNA dels (long
range PCR)
P4 F 64 57 Ptosis, multiple sclerosis n.a. COX- (0.4%) c.662C > G,
p.Ala221Gly
mtDNA dels (long
range PCR)
EMG, electromyography; N, normal; M, myopathic; n.a, not assessed; COX-, Cytochrome c Oxidase negative fibers; RRF, Ragged Red fibers;
mtDNA dels, mitochondrial DNA multiple deletions; SB, Southern Blot.
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laboratory analysis that excluded myasthenia. Her neuro-
logical examination was unremarkable, except for bilateral
ptosis. Laboratory exams showed a mild hyper-CKemia
(232 U/L, n.v. <145 U/L). Muscle biopsy (biceps), per-
formed at 69 years of age, revealed a few COX-negative
fibers (0.2%).
Patient 4 is a 64-year-old woman with a history of
relapsing/remitting multiple sclerosis that started at
50 years and was treated with interferon and
corticosteroids. At 57 years she developed ptosis in the
right eye, followed by ptosis in the left eye some years
later, slowly progressive, without diplopia. Electrophysio-
logical and laboratory analysis excluded myasthenia. Her
neurological examination showed a bilateral ptosis, with-
out ophthalmoplegia and spastic paraparesis. Family his-
tory was negative for neurological disorders. Muscle
biopsy (biceps), performed at 64 years of age, showed
scattered COX-negative fibers (0.4%).
Figure 1. Novel DNA2 variants identified in this study. (A) A scheme of human DNA2 including the location of the mutations so far identified in
the coding sequence (red color indicates the novel variants presented here). The diagram shows the functional domains conserved in this enzyme.
(B) Homology model of DNA2 with adenosine diphosphate (ADP) (pink) binding in the catalytic center of the ATPase domain (blue) interacts with
ssDNA (orange). The positions of four residues, Ala221, Ser 640, Ser552 and Arg956, are illustrated as red sticks.
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Methods
Genes involved in mtDNA maintenance disorders were
ruled out using direct sequencing (Patients 1 and 2) or
gene-panel sequencing (Patients 3 and 4) starting from
blood-derived DNA. Coding exons and intronic bound-
aries of human DNA2 (NM_001080449.2) were analyzed
as described.4 Enzymatic studies performed on purified
recombinant DNA2 proteins were performed as previ-
ously described.3,4 Additional details on experimental pro-
cedures are included in the Data S1 section.
Results
All probands displayed multiple mtDNA deletions in
muscle samples detected by Southern blot or long range
PCR analysis (Fig. S2). DNA2 sequencing revealed the
presence of the following heterozygous mutations
(Fig. 1A), resulting in the amino acid substitutions:
c.1919C > T (p.Ser640Leu, Patient 1), c.2867G > A
(p.Arg956His, Patient 2), c.1655C > T (p.Ser552Leu,
Patient 3) and c.662C > G (p.Ala221Gly, Patient 4). Two
variants displayed very low frequency in gnomAD data-
base (https://gnomad.broadinstitute.org c.2867G > A:
4.2E-06 and c.662G > C: 1.37E-05).
Segregation analysis was positive in the available
affected relatives of Patient 1, whereas no mutation was
detected in the asymptomatic daughter.
The mutations affect residues well conserved in mam-
malian DNA2 orthologues, with the exception of
p.Arg956 (Fig. S3). The tridimensional modeling of
DNA2 was used to predict the potential consequences of
the identified variants on protein structure and activity
(Fig. 1B). We also expressed and purified recombinant
wild type and mutant DNA2 proteins to check the impact
of the mutations on nuclease and ATPase activities
(Fig. 2A and 2B).
The amino acid change Ser640Leu in helicase 1A
domain results in the loss of the hydrogen bond with
Arg781, hampering the binding of ssDNA. The mutation
was found to abolish both nuclease and ATPase activities.
The Arg956His mutation falls within the helicase 2A
domain and it is predicted to affect the ssDNA binding
via allosteric effect on positively charged residues Arg944
and Lys968. Biochemical studies did not show a signifi-
cant impact on DNA2 activities.
The substitution Ala221Gly affects the nuclease domain
and may weaken core hydrophobic interaction for a helix
bundle that contacts the nuclease catalytic center. Bio-
chemical studies confirmed a modest, but significant,
decrease of both endonuclease and ATPase activities com-
pared to wild type protein.
The change Ser552Leu affects the barrel domain, result-
ing in the loss of the hydrogen bond with Asn550 likely
leading to destabilization of the loop structure and weak-
ening the ssDNA binding domain. Both nuclease and
ATPase activities are affected by the presence of the vari-
ant.
To mimic the heterozygous nature of the variants, we
also mixed the WT DNA2 with equal amounts of WT
and mutant forms of the protein (Fig. 2C). Compared to
reactions with WT/WT proteins, the product of reactions
of WT/Ser640Leu, WT/Ala221Gly and WT/Ser552Leu
were decreased supporting the hypothesis that WT DNA2
cannot fully compensate the detrimental effects of the
mutations.
Discussion
In this study we expanded the list of DNA2 mutations
linked with adult onset presentations. Clinical features of
the novel probands mainly show muscle involvement
(ptosis, muscle weakness). Peripheral neuropathy, diabetes
and cataract were also observed. A heterogenous COX-
negative pattern was observed at muscle biopsy. COX-
negative fibers were especially rare in Patients 1, 3 and 4
in which muscle involvement was restricted to extraocular
muscles. This finding can be attributed to secondary age-
Figure 2. Biochemical studies (A) ATPase activity of WT and altered forms of DNA2. 100 ng WT and mutants of DNA2 were incubated with
1 mmol/L ATP and 1 lg 22 bp ssDNA for 10, 20, 40 and 60 min, respectively. ATPase activity of WT or mutant DNA2 proteins was assayed using
the adenosine diphosphate (ADP)-GloTM Max Assay kit (Promega). Values are means  SEM of ATPase activities (percent of ATP-to-ADP
conversion) of three independent assays. (B) Endonuclease activities of WT and altered forms of DNA2. Top panel is the substrate mimicking Flap
Okazaki fragment. Arrows indicate cleavage sites. 0.5 ng of WT, p.Ala221Gly, p.Ser552Leu, p.Ser640Leu and p.Arg956His were respectively
incubated with 0.5 pmol 50-end 32P-labeled substrate. Reactions were performed at 37°C for 5, 10, 15 and 20 min. “Sub.” indicates substrate,
“Prod.” indicates cleavage product. Bottom panel shows the quantification of DNA2 cleavage products. The relative nuclease activity was
calculated by dividing the intensity of the product bands by the sum of the intensities of product and substrate bands in each reaction. Values are
means  SEM of nuclease activities (percent of cleavage products) of three independent assays. (C) Heterogeneity effects of the nuclease activity
of altered forms of DNA2. 0.25 ng WT DNA2 protein was mixed with 0.25 ng p.Ala221Gly, p.Ser552Leu, p.Ser640Leu and p.Arg956His,
respectively. The mixture was incubated with 0.5 pmol 50-end 32P-labeled substrate. Reactions were performed at 37°C for 5, 10, 15 and 20 min.
Bottom panel shows the quantification of DNA2 cleavage products. Values are means  SEM of three independent assays. In each panel, the P-
value was calculated using a Student’s t test.
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related changes or, more likely, to the limited informa-
tiveness of the muscles sampled. Indeed, extraocular mus-
cles tend to show a greater prevalence of COX-negative
and RRF fibers compared to limb muscles in adult sub-
jects.8
Heterozygous truncating mutations have been recently
associated with pediatric presentation featuring congenital
muscle hypotonia, with ptosis6 or multiple joint frac-
tures.7 A homozygous truncating mutation was proposed
as the underlying cause of a form of dwarfism (Seckel
syndrome) in a Saudi Arabian pedigree showing consan-
guinity.5 It is likely that severe mutations affecting in part
(haploinsufficiency) or totally abrogating DNA2 expres-
sion might show profound consequences on DNA2 activ-
ity, which in turn reflects on mtDNA content (severe
mtDNA depletion), leading to congenital severe presenta-
tions.
As we previously observed,4 DNA2 missense mutations
often produce a detrimental effect on multiple domains
impairing both nuclease and ATPase activities. In this
study only the DNA2 Arg956His mutation did not differ
from wild type enzyme. This variant lies in the helicase
domain 2A and it is predicted to alter the binding of sin-
gle strand DNA, hampering DNA replication. Although
helicase function was considered dispensable for the DNA
end resection, recent studies suggest this domain might
facilitate the traversal of DNA2 over the RNA primer
associated with Okazaki fragments.9 We cannot exclude
that the variant identified in Patient 2 might impact this
mechanism, which still needs to be confirmed for
mtDNA. In this regard, the study of the biochemical
defects underlining mitochondrial disorders featuring
mtDNA instability has increased our knowledge of the
proteins involved in mtDNA replication and repair such
as DNA2 and its partners MGME110 and RNaseH1.11
Abnormal regulation of DNA2 activity might also result
in nuclear DNA stress, impairment of its repair mecha-
nism and genomic instability as supported by experiments
in reconstituted systems and in human cells.12,13 Indeed,
downregulation14 or overexpression15 of DNA2 activity
have been observed in human tumors. It is tempting to
speculate that even germline inherited DNA2 mutations
might predispose to cancer, as suggested by the high inci-
dence of different forms of neoplasia in Patient 1’s pater-
nal relatives.
Mutations in DNA2 are a rare cause of mitochondrial
disease, with independent mutated subjects now repre-
senting the 2.7% of our cohorts of adult patients with
mtDNA maintenance disorders (5.2% of undiagnosed
cases). The prevalence of limb-girdle weakness prompts to
include DNA2 analysis in diagnostic gene panels for neu-
romuscular patients, even in the absence of additional
clues directing towards mitochondrial dysfunction.
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